Gordon Campbell | Parliament TV | Parliament Today | Video | Questions Of the Day | Search


Major Initiative for Biotech

Hon Jim Anderton
Minister for Economic, Industry and Regional Development
Hon Pete Hodgson
Minister of Research, Science and Technology

1 September 2003
Media statement

Major Initiative for Biotech

World-leading diabetes treatments will continue to be developed in New Zealand by Auckland biotechnology company, Protemix, which has just received a $2 million underwrite by Investment New Zealand for possible funding for Protemix from existing programmes provided by the Foundation for Research Science and Technology.

Protemix will also receive an $18 million capital injection by a New Zealand consortium headed by Birnie Capital Partners.

One of Protemix's diabetes drugs has already been fast tracked by the United States Federal Drug Administration because of its potential significance.

"I am very pleased that a collaboration between Investment New Zealand and Birnie Capital Partners has ensured that Protemix will continue its drug developments with a view to commercialising them internationally," said Economic, Industry and Regional Development Minister Jim Anderton.

Protemix has attracted significant interest from American venture capitalists for further development of its diabetes treatments. Along with the $18 million raised by Birnie Capital Partners, the Government's $2 million underwrite, is reflective of the Government’s commitment to grow the biotech industry in New Zealand.

Jim Anderton and Research, Science and Technology Minister Pete Hodgson announced today that Investment New Zealand's Strategic Investment Fund will provide a $2 million guarantee for technology assistance support. Protemix will apply to FRST under its existing programmes and criteria and any difference between the available assistance through FRST and $2 million will be underwritten by Investment New Zealand.

Protemix develops new therapies for diabetes and associated cardiovascular disease, as well as for metabolic disorders. It has a number of diabetes-related drugs under development, including one potential "blockbuster" - capable of generating annual revenue of US$750 million or more - for diabetic heart disease. The compounds were developed by Protemix’s scientific team based at the University of Auckland led by internationally-regarded New Zealand biochemist Professor Garth Cooper and diabetes physician Associate Professor John Baker.

"Protemix is an example of the world class capability of the New Zealand biotech industry," Mr Hodgson said. "Its presence in New Zealand will inevitably attract more interest from overseas investors and give confidence to other biotech players that there is a commitment to help them take their discoveries through to commercialisation.

"This deal is a milestone in the development of a New Zealand biopharmaceutical industry. "It will help New Zealand retain and recruit the pool of scientists, business people and scientific entrepreneurs it needs to participate in the global biopharmaceutical market."

The Strategic Investment Fund
The Strategic Investment Fund is administered by Investment New Zealand to support significant direct investment in New Zealand which can bring tangible benefits to New Zealand. It is equally available to New Zealand and overseas businesses looking to establish or expand significant business operations in New Zealand.

The Strategic Investment Fund will:
- complement the private sector's role
- involve partnership and co-operation between central and local government, educational and research institutions and the private sector
- co-ordinate with the activities of other government programmes
- require clear commitment from potential investors
- be in line with New Zealand's international obligations
- clearly demonstrate sufficient cost benefits to be worthwhile in the short and long-term, and directly and indirectly.
That the investment:
- involves net new investment of at least $50 million over 5 years, and/or able to create 200 new jobs in 5 years
- would not occur in New Zealand without support from the Fund
- complements New Zealand's areas of competitive advantage
- has no negative competitive consequences domestically
- would involve a high level of clear spillover benefits.

Protemix is a biopharmaceutical company co-founded by Dr Garth Cooper and Dr John Baker, which is involved in the discovery and development of new medicines for diabetes and heart diseases.


Protemix -
Investment New Zealand -
Technology New Zealand -

© Scoop Media

Parliament Headlines | Politics Headlines | Regional Headlines

Scoop 3.0: How You Can Help Scoop’s Evolution

Entering into its third decade of operation, the Scoop news ecosystem is set to undergo another phase of transformation and evolution.

We have big plans for 2018 as we look to expand our public interest journalism coverage, upgrade our publishing infrastructure and offer even more valuable business tools to commercial users of Scoop. More>>


Speaking Of Transport: Public Engagement On Wellington Scenarios

“Our work on possible solutions for Wellington’s transport future is ongoing, but has progressed to the stage where we’re ready to share our ideas with the public and seek their feedback to help guide our next steps...” More>>


Parental Leave: National's Time-Sharing Change Fails

National has proposed a change to the Parental Leave and Employment Protection Amendment Bill that would allow both parents to take paid parental leave at the same time, if that is what suits them best. More>>


Train Free Thursday: Workers Strike To Defend Terms Of Employment

"They signed up to these conditions a year ago when they got the contract for Wellington's rail services. Now they're trying to increase profits by squeezing frontline workers." More>>


Seclusion: Ombudsman Emphasises Importance Of Monitoring

Disability Rights Commissioner Paula Tesoriero says that while there have been changes to the Education (Update) Amendment Act 2017 to prohibit the use of seclusion, the report is an important reminder of the importance of regular monitoring of schools. More>>


United Future History: "All Good Things Must End"

'We’re extremely proud of what we’ve achieved over the past 15 years, working alongside the government of the day, both National and Labour.' Mr Light told members on Monday. More>>

Gordon Campbell: On The TPP Outcome, And The Hobbit Law

Somehow the Trans Pacific Partnership trade deal has come lurching back from the dead – and as predicted in this column last week, the member countries gathered in Vietnam have announced a deal in broad principle, shunted aside until a later date the stuff on which they don’t agree, and declared victory. More>>

Agreeing To Differ: Greens Maintain Opposition To TPPA
“The Green Party has long opposed the TPPA. The new proposed deal, which came out of the weekend’s talks, still contains key ISDS concessions to corporations that put our democracy at risk, so our position remains the same,” said Green Party trade spokesperson Golriz Ghahraman. More>>


Monitoring Report: A New Chapter For Children’s Rights In New Zealand?

The Children’s Commissioner is calling on the country to embrace children’s rights to ensure their overall well-being. More>>





Featured InfoPages

Opening the Election